Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

@article{Horby2020AzithromycinIH,
  title={Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial},
  author={Peter W. Horby and Alistair J. Roddick and Enti Spata and Natalie Staplin and Jonathan R. Emberson and Guilherme Pessoa-Amorim and Leon Peto and Mark Campbell and Christopher E. Brightling and Benjamin Prudon and David R. Chadwick and Andrew P. Ustianowski and Abdul Ashish and Stacy Todd and Bryan Yates and Robert Christians Buttery and S. Scott and Diego Maseda and John Kenneth Baillie and M. H. Buch and Lucy C. Chappell and Jeremy N Day and Saul N. Faust and Thomas F. Jaki and Katie Jeffery and Edmund Juszczak and Wei Shen Lim and Alan A. Montgomery and Andrew D. Mumford and Kathryn M. Rowan and Guy E. Thwaites and Marion M. Mafham and Richard Haynes and Martin J Landray},
  journal={medRxiv},
  year={2020}
}
Background: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We evaluated the efficacy and safety of azithromycin in hospitalised patients with COVID-19. Methods: In this randomised, controlled, open-label, adaptive platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or… Expand
Antibiotics for the treatment of COVID-19.
TLDR
The efficacy and safety of antibiotics compared to each other, no treatment, standard of care alone, placebo, or any other active intervention with proven efficacy for treatment of COVID-19 outpatients and inpatients is assessed. Expand
A Systematic Review and Network Meta-Analysis for COVID-19 Treatments
TLDR
The Bayesian NMA identified superiority of several COVID-19 treatments over SOC in terms of mortality, requirement of MV, hospital discharge and viral clearance, and shed new light on further research and discovery of potential COIDs. Expand
In Vitro Assessment for Dose Preparation and Simulated Administration of Azithromycin Suspensions via Enteral Feeding Tubes
Administration of medication via enteral feeding tubes (EFT) is common in cases where patients are unable to swallow the dosage form or a patient is intubated. The SARS-CoV-2 (COVID-19, coronavirus...
Disputes over the production and dissemination of misinformation in the time of COVID-19
TLDR
Risks deriving from misinformation about how to treat patients who have tested positive for SARS‐CoV‐2 and who are asymptomatic or have mild symptoms are highlighted and management at home is deemed appropriate. Expand
Medikamentöse Therapie bei COVID-19 mit Bewertung durch die Fachgruppe COVRIIN am Robert-Koch-Institut
Autoren und wird Ihre Fragen und Anregungen weiterleiten. Stand: 08.07.2021; DOI 10.25646/7743.10 1 Medikamentöse Therapie bei COVID-19 mit Bewertung durch die Fachgruppe COVRIIN am RobertExpand

References

SHOWING 1-10 OF 30 REFERENCES
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  • Peter W Marion Jennifer L Louise Natalie Jonathan Adrian Horby Mafham Bell Linsell Staplin Emberson Palfree, P. Horby, +24 authors M. Landray
  • Medicine
  • The Lancet
  • 2020
TLDR
In patients admitted to hospital with COVID-19, lopinavir–ritonavir was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. Expand
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial
TLDR
Hydxychloroquine-azithromycin combination may be beneficial for individuals who are known to have a very low underlying risk for cardiac arrhythmias based on the ACC criteria and has a better general condition. Expand
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.
TLDR
In patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death. Expand
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
TLDR
Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. Expand
Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines
TLDR
There is weak evidence on the antiviral and immunomodulating effects of azithromycin, which in addition is not based on results from COVID-19 patients specifically, so this antibacterial should be considered only as empirical treatment of community-acquired pneumonia (CAP), although not all current treatment guidelines are in agreement. Expand
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
TLDR
In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support. Expand
Efficacy of Clarithromycin‐Naproxen‐Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open‐label Randomized, Controlled, Phase IIb/III Trial
TLDR
Combination treatment reduced both 30‐ and 90‐day mortality and length of hospital stay and the virus titer and PSI and the NPA specimens with NIRV quasispecies ≥ 5% were significantly lower in the combination treatment group. Expand
Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials
TLDR
Whether the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization varies between subgroups related to treatment characteristics, disease severity at the time of randomization, patient characteristics, or risk of bias is examined. Expand
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
TLDR
In this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Expand
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
TLDR
In study participants, mortality was high, independent risk factors were increasing age, male sex, and chronic comorbidity, including obesity, and the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks is shown. Expand
...
1
2
3
...